Biotec BetaGlucans AS is the operating unit within the Biotec Pharmacon Group handling R&D and manufacturing of beta-1,3/1,6- glucans from yeast. Biotec BetaGlucans operates a production facility and quality control lab that are both GMP and ISO 13485 certified.
The scientific background for the beta-glucan activity in the company has roots back the discoveries at the University of Tromsø and work performed after the early initiation of Biotec Pharmacon.
During the recent years the awareness and general research on the immunomodulatory potential of beta-glucans has increases significantly within biomedical and clinical research communities. The company’s development of beta-glucan based products for treatment of immune related diseases and disorders has accordingly gained increased attention within the scientific community.
The basis for product pipeline is the soluble beta-glucan (SBG®), and on the top of the product pipeline you find Woulgan® Biogel. This is an advanced wound healing product, CE-marked as a medical device under class 3, rule 13 as from April 2014. Other applications of SBG in medical devices are under evaluation.
In addition to having a well-defined potential in wound treatment, SBG is in development for treatment of cancer in combination with both vaccines and antibodies. A program on the use of SBG to treat Inflammatory Bowel Disease has also been initiated by the company.